BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/24/2025 9:58:08 AM | Browse: 126 | Download: 106
 |
Received |
|
2025-05-20 06:50 |
|
Peer-Review Started |
|
2025-05-20 06:50 |
|
First Decision by Editorial Office Director |
|
2025-05-24 02:46 |
|
Return for Revision |
|
2025-05-24 02:46 |
|
Revised |
|
2025-06-05 01:31 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-04 02:51 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-04 06:32 |
|
Articles in Press |
|
2025-09-04 06:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-20 05:50 |
|
Publish the Manuscript Online |
|
2025-10-24 09:58 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Sodium-glucose cotransporter 2 inhibitor in heart failure patients and their outcomes: A meta-analysis of randomized controlled trials
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Saketh Parsi, Pallavi D Shirsat, Lakshmi P Mahali, Salim Surani and Rahul Kashyap |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salim Surani, Professor, Department of Medicine and Pharmacology, Texas AM University, 40 Bizzell Street, College Station, TX 77843, United States. srsurani@hotmail.com |
| Key Words |
All-cause mortality; Cardiovascular deaths; Hospitalizations for heart Failure; Heart failure; Sodium-glucose cotransporter 2 inhibitor |
| Core Tip |
Sodium-glucose cotransporter 2 (SGLT2) inhibitor have been incorporated into heart failure (HF) treatment guidelines due to their established benefits in patients with HF. They can be initiated in HF patients irrespective of their diabetes history. These medications significantly lower the risk of hospitalization for HF. SGLT2 inhibitor may also reduce cardiovascular deaths and all-cause mortality in HF patients, though the statistical significance of these outcomes has not been consistently demonstrated across all studies. |
| Publish Date |
2025-10-24 09:58 |
| Citation |
Parsi S, Shirsat PD, Mahali LP, Surani S, Kashyap R. Sodium-glucose cotransporter 2 inhibitor in heart failure patients and their outcomes: A meta-analysis of randomized controlled trials. World J Cardiol 2025; 17(10): 109731 |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i10/109731.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i10.109731 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
